Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (151-160 of 420) with videos related to

Pageof 42
Sort By:
Antimicrobial Agents and Chemotherapy|March 25, 2015
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumoniaHelio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniaeRonald N Jones, Helio S Sader, Matthew G Stilwell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 18, 2007
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 13, 2007
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2009
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)Thomas R Fritsche, Helio S Sader, Matthew G Stillwell, et al.
Diagnostic Microbiology and Infectious Disease|October 9, 2007
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Surgical Infections|March 19, 2016
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical CentersHelio S Sader, David J Farrell, Robert K Flamm, et al.
The Pediatric Infectious Disease Journal|December 6, 2017
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)Helio S Sader, Michael D Huband, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2012
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continentsRodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016Helio S Sader, Rodrigo E Mendes, Jennifer M Streit, et al.
Pageof 42

Showing results (151-160 of 420) with videos related to

Sort By:
Pageof 42
Antimicrobial Agents and Chemotherapy|March 25, 2015
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumoniaHelio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniaeRonald N Jones, Helio S Sader, Matthew G Stilwell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 18, 2007
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 13, 2007
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2009
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)Thomas R Fritsche, Helio S Sader, Matthew G Stillwell, et al.
Diagnostic Microbiology and Infectious Disease|October 9, 2007
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Surgical Infections|March 19, 2016
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical CentersHelio S Sader, David J Farrell, Robert K Flamm, et al.
The Pediatric Infectious Disease Journal|December 6, 2017
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)Helio S Sader, Michael D Huband, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2012
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continentsRodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016Helio S Sader, Rodrigo E Mendes, Jennifer M Streit, et al.
Pageof 42